Inqovi

Active Ingredient(s): Decitabine + Cedazuridine
FDA Approved: * July 7, 2020
Pharm Company: * ASTEX PHARMACEUTICALS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Inqovi Overview

Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dosed combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).[1][2] It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.[1][2] The most common side effects of decitabine/cedazuridine include fatigue, constipation, hemorrh...

Read more Inqovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Decitabine/cedazuridine

Recent Inqovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Decitabine + Cedazuridine
  • Tablet: 100mg + 35mg, 35mg + 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (3 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 8 August 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA